The Russian company Promomed has initiated the first phase of a clinical trial for the first Russian generic of the drug for obesity and diabetes developed by Eli Lilly, containing the international nonproprietary name tirzepatide.
The study, which will involve 173 volunteers, will examine the safety, tolerability and immunogenicity of tirzepatide from Promomed (WRYС12201). The experiment will take place in Moscow at the Bessalar private clinic.
The reference drug Mounjaro, which contains the INN tirzepatide, was originally developed for the treatment of diabetes. It was approved in the US in 2022. In November 2023, the FDA approved tirzepatide (Eli Lilly’s Zepbound) for weight loss. The development is protected by a US patent until 2036.